Contineum Therapeutics Updates Clinical Development Milestones and Reports Q2 2025 Financial Results.
ByAinvest
Tuesday, Aug 5, 2025 4:07 pm ET1min read
CTNM--
Contineum Therapeutics reported Q2 2025 financial results and updated key clinical development milestones. The company expects topline data from its PIPE-307 Phase 2 RRMS trial in Q4 2025, topline data from its PIPE-791 Phase 1b PET trial in Q3 2025, and initiation of its global PIPE-791 Phase 2 proof-of-concept clinical trial in IPF in Q4 2025. The company has postponed the initiation of its planned PIPE-791 PrMS and CTX-343 clinical trials and anticipates topline data from its exploratory PIPE-791 Phase 1b trial in patients with chronic pain in H1 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet